Otsuka to Pay Lundbeck $825 Million for Alzheimer’s DrugMakiko Kitamura and Kristen Hallam
Otsuka Holdings Co. agreed to pay H. Lundbeck A/S as much as $825 million to develop an experimental Alzheimer’s treatment. Lundbeck shares rose the most in more than four years in Copenhagen trading.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.